CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and
improves overall survival (OS) in a minority of metastatic melanoma (MM) patients. We …

Stage IV metastatic melanoma patients historically have a poor prognosis with 5–10% 5-
year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 …

Purpose Ipilimumab, a fully human monoclonal antibody specific to CTLA-4, has been
shown to improve overall survival in metastatic melanoma patients. As a consequence of …

Ipilimumab (IPI) blocks CTLA-4 immune checkpoint resulting in T cell activation and
enhanced antitumor immunity. IPI improves overall survival (OS) in 22% of patients with …

Purpose: Treatment with ipilimumab can cause objective tumor responses in patients with
metastatic melanoma. We have treated 177 evaluable patients in three clinical trials and …

2555 Background: Increasing doses of ipilimumab, an antibody to CTLA-4, is associated
with a higher likelihood of clinical benefit. Analysis of pharmacodynamic biomarkers shows …

Background Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and,
in the US, as adjuvant treatment for high risk melanoma radically resected. The use of …

The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces
immune-mediated long-term control of metastatic melanoma in a fraction of patients …

Targeted biologic therapies such as anti–cytotoxic T lymphocyte antigen (CTLA-4)
monoclonal antibodies, either as monotherapy or in combination with chemotherapy or …

Metastatic melanoma is a rapidly spreading cancer whose prognosis remains poor although
important therapy advances in recent years. Ipilimumab, an anti-CTLA-4 immunotherapy …